BPE has created a very high scientific level Festival dedicated to pharmacoepidemiology: the Bordeaux PharmacoEpi Festival, which is organized since 2010 (eight editions of the Festival have been held to date).
World-class experts talk about a topic of their choice. This original master class format allows all participants to be in front line on the major news of the discipline as well as on hot topics in public health.
| Edition 2021 |
|
Bordeaux PharmacoEpi Festival
9th edition, May 25th to June 1st 2021 HYBRID EVENT World-class experts will talk about the topics of their choice in 2 hours sessions in live streaming or face-to-face at the University of Bordeaux View Replay |
| 2019 edition | ||
|
Catherine Quantin
Dijon |
The validity of diagnoses in public health databases (with invited speakers) | |
|
Tania Schink
Bremen, Germany |
Internal validation of outcomes in public health databases | |
|
Giuseppe Traversa
Rome, Italy |
Governing pharmaceutical care: Do we need to worry about the "excessive" prices of drugs? A pharmacoepidemiologist perspective | |
|
Gianluca Trifiró
Messine, Italy |
Challenges in postmarketing surveillance of biologics in the era of biosimilars | |
|
Bernard Bégaud
Bordeaux |
[General Public Conference] A quoi peut servir la pharmacoépidémiologie ? | |
|
Kristian B. Filion
Montreal, Canada |
The safety of antidiabetic drugs, and Distributed Drug Safety Networks/CNODES | |
|
Ron Herings
Amsterdam, NL |
Scenario and prediction modeling In pharmacoepidemiology for health personalization | |
| 2018 edition | ||
|
Munir Pirmohammed
Liverpool, UK |
The excitement and challenges of being a clinical pharmacologist | |
|
Jacques Le Lorier
Quebec, CA |
The Pharmacologically Pertinent Period of Effect. Are the editors doing their job ? | |
|
Susana Perez-Gutthann
Barcelona |
Looking behind the code | |
|
Corinne de Vries
London, UK |
Drug safety in pregnancy | |
|
Tom Walley
Liverpool, UK |
Clinical research in the UK | |
|
John Ioannidis
Stanford, USA |
Reproducible and useful epidemiology: why and how | |
| 2017 edition | ||
|
Andy Stergachis
Seattle, USA |
How to communicate benefits and risks, based on pharmacoepidemiological studies | |
|
Jesper Hallas
Odense - Denmark |
Pharmacovigilance in low- and middle-income countries: need, issues, methods, case studies, and future directions. | |
|
Gerard de Pouvourville
Paris |
Pharmacoeconomics in the modern world. | |
|
Til Stürmer
North Carolina, USA |
Principled versus pragmatic pharmacoepidemiology: do we need to take sides? | |
|
Jaime Caro
Boston, USA |
The use of DICE simulation for epidemiologic models | |
|
Marc Rodwin
Boston, USA |
1) How can inappropriate off-label drug use be managed? 2) Financial relations between pharmaceutical firms and physicians |
|
| 2015 edition | ||
|
Arnold Chan
Taipei, Taiwan |
Pharmacoepidemiology and drug safety in Asia. | |
|
Jerry Avorn
Boston, USA |
Patients, doctors and drug safety | |
|
Sonia Hernandez-Diaz
Boston, USA |
Are babies the only outcomes in pregnancy? | |
|
Stella Blackburn
London, UK |
Considerations on risk-benefit assessment | |
|
Bert Leufkens
Utrecht, NL |
Pharmacovigilance is here to stay | |
| 2014 edition | ||
|
Saad Shakir
Boston, USA |
Risk Management in Pharmacovigilance: what is under the bonnet? | |
|
Joshua Gagne
Boston, USA |
Disease risk scores in pharmacoepidemiology? | |
|
Patrick Ryan
Philadelphia, USA |
Lessons in pharmacoepidemiology from the Observational Medical Outcomes Partnership | |
|
Martijn Schuemie
Rotterdam, NL |
More Lessons in pharmacoepidemiology from the Observational Medical Outcomes Partnership | |
|
Morten Andersen
Stockholm, Suède |
How things happen in the Nordic countries? | |
|
Darren Toh
Boston, USA |
Prospective surveillance of newly approved medical products | |
| 2013 edition | ||
|
Nancy Dreyer
Boston, USA |
Observational Studies of Effectiveness and Safety: Practical Applications and Challenges | |
|
Ken Rothman
Boston, USA |
Ten Persistent Research Fallacies1. The randomized trial represents the perfect study design.2. Results from case-control studies are weaker than those from cohort studies, and the results from cohort studies are weaker than those from randomized trials.3. Study subjects should be representative of target populations.4. When measuring rates, the person-time of exposure to an agent goes in the denominator.5. The control group in ca-co studies should be just like the cases except that they don't have disease. | |
|
Ken Rothman
Boston, USA |
Ten Persistent Research Fallacies (cont'd)6. When conducting multiple comparisons, take the number of comparisons into account when obtaining p-values.7. Account for missing data with an indicator term for "missingness" in a model8. A good way to categorize a variable is by quartiles or quintiles 9. A reasonable way to interpret data is by using significance tests10. Report power when reporting the results of a study. | |
|
Samy Suissa
Montreal, Canada |
Time-related biases in pharmacoepidemiology: Randomized trials built on sand. | |
|
Jacques Benichou
Rouen |
Attributable and competitive risks in pharmacoepidemiology | |
| 2011 edition | ||
|
Syd Shapiro†
Capetown, South Africa |
Oligognostic mega-analysis. Is Archie turning in his grave? | |
|
Michal Abrahamowicz
Montreal, Canada |
Modeling the effects of time-varying drug exposures: alternative models, cumulative effects and further challenges | |
|
Olaf Klungel
Utrecht, The Netherlands |
Improved control for confounding using propensityscores and instrumental variables | |
|
Jeremy Rassen
Boston, USA |
Computational pharmacoepi - the frontier between computing and PE | |
|
Tobias Kurth
Paris/Bordeaux |
The evaluation of different treatment effects in subgroups: practical uses of propensity scores | |
|
Bernard Bégaud
Bordeaux |
« Who cares about The truth? Non-comparative comparisons are safer », the Guru says. | |
| 2010 edition | ||
|
Tom MacDonald
Dundee, Scotland |
A rant about everything that irritates me including data protection, privacy, consent, regulation and ethics, interspersed with singing, art, poetry, philosophy (home-spun and otherwise), fantasy worlds (where are we now) and perfect worlds (will we ever get there?) a bit about risks (to individuals) and benefits (to society), duty of care, politics, changing the world, how we and ISPE can do this and other random thoughts including expressing ideas that are not my own or new and more singing". | |
|
Yola Moride
Montreal – Canada |
Why do I bother doing teleconferences in the middle of the night for data safety monitoring boards when nobody cares about denominators? | |
|
Stephen Evans
London UK |
Pharmacoepidemiology and the pharmaceutical industry: undermined by their lawyers & tarnished by their funding? | |
|
Judith K Jones
Fairfax, Degge group, USA |
The smorgasboard of exposure options- drugs, biologics, vaccines, devices --how long do you count the biological effect in a population study...? | |
|
Miriam Sturkenboom
Rotterdam, NL |
The european database festival:one happy family? | |
|
Alexander Walker
Boston, USA |
Signal Detection | |